ISHL HL Update 2021 | NIVAHL: nivolumab and AVD in early-stage unfavorable HL
Paul Jan Bröckelmann
• 11 Mar 2021
Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, outlines results of the NIVAHL trial (NCT03004833), a prospective, randomized Phase II study evaluating nivolumab and doxorubicin, vinblastine, and dacarbazine (AVD) in patients with early-stage unfavorable classical Hodgkin lymphoma (HL). Nivolumab-based first-line treatment led to high remission rates and excellent 12-month progression-free survival and warrants further evaluation in this patient population. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
